Physician profile
Sheri E Spirt
NPI 1831257591
$59,513.48
in general payments reported to CMS, 2019-2025
21 companies · $5,922 in 2025
The $5,922 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,773 · 2020: $14K · 2021: $7,581 · 2022: $9,799 · 2023: $9,593 · 2024: $4,580 · 2025: $5,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $3,997 · Travel and Lodging: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,400.00 |
| Food and Beverage | $3,996.88 |
| Travel and Lodging | $1,698.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33,104.49 | 2021-2025 | Vraylar |
| Allergan, INC. | $21,564.02 | 2019-2021 | |
| Lundbeck LLC | $764.53 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $688.69 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $544.63 | 2021 | |
| Alkermes, INC. | $509.09 | 2024-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $476.59 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $424.97 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $328.50 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $290.27 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $207.45 | 2022-2024 | Auvelity |
| Bausch Health US, LLC | $163.35 | 2019-2024 | Wellbutrin, Aplenzin |
| Sage Therapeutics, LLC | $155.65 | 2023-2024 | |
| Corium, LLC | $88.05 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $68.33 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $38.55 | 2021 | |
| Ironshore Pharmaceuticals INC. | $21.75 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.19 | 2019 | |
| Almatica Pharma LLC | $20.32 | 2023 | Loreev Xr, Sertraline Hcl |
| Arbor Pharmaceuticals, INC. | $17.67 | 2021 | |
| Currax Pharmaceuticals LLC | $15.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheri Spirt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.